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Effect of Hypertension on the
Progression of Chronic Renal Failure in Children
Marianne Soergel and Franz Schaefer
This article reviews the current state of knowledge
concerning the vicious cycle of hypertension and pro-
gressive loss of renal function in renal disease, as well as
the renoprotective potential of antihypertensive treat-
ment, with a specific focus on children and adolescents.
Deficient arteriolar autoregulation renders damaged
kidneys particularly sensitive to systemic high blood
pressure (BP). Intraglomerular hypertension promotes
proteinuria, which further activates the renin-angiotensin
system (RAS). Angiotensin II, apart from its vasoconstric-
tor effects, induces local proinflammatory and profibrotic
signaling molecules resulting in renal scarring. The
activity of the scarring process with the resultant loss of
functional renal mass appears to be modulated, in part, by
a polymorphism in the angiotensin converting enzyme
(ACE) gene. Clinical studies in adults have demonstrated
convincingly the high risk of progression of chronic renal
failure (CRF) associated with high BP, the benefit of
lowering BP to even the low normal range, and the
specific benefit of drugs that inhibit the RAS on the
progression of CRF. In children, even moderately elevated
BP and moderate proteinuria have been shown to be
significant risk factors for progression and CRF. The op-
timal target BP for children with CRF is currently being
determined in a multinational, randomized, prospective
trial. Am J Hypertens 2002;15:53S–56S © 2002 Amer-
ican Journal of Hypertension, Ltd.
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C hronic renal disease is associated with high bloodpressure (BP), and hypertension has more recentlyreceived additional attention for its close correla-
tion to the progressive loss of renal function. This is of
particular interest in pediatric nephrology, as severe hy-
pertension in children predominantly affects patients with
renal diseases. In contrast to the cardiovascular sequelae of
childhood-onset essential hypertension, such as left ven-
tricular hypertrophy and vascular damage, which may not
become clinically relevant before adulthood, rapid pro-
gression of renal insufficiency may result in end stage
renal insufficiency during childhood.
This article reviews the actual knowledge on causes and
effects in the vicious cycle of hypertension and progressive
loss of renal function, as well as the renoprotective poten-
tial of antihypertensive treatment, with special attention to
the pediatric age group.
Why Hyertension Is So
Bad for Damaged Kidneys
Healthy kidneys protect their glomerular tufts from the
effects of systemic BP variability by judicious adaptation
of their afferent arteriolar tone, leading to a stable filtration
pressure over a wide range of systemic BP (Fig. 1). This
autoregulation is thought to be deficient in chronic renal
failure (CRF),1 and the correlation of glomerular filtration
rate (GFR) and proteinuria to systemic BP in humans with
nephropathies strongly supports this view.2 In addition,
systemic or local angiotensin II induces constriction, es-
pecially of the efferent arteriole, thereby further increasing
the intraglomerular pressure.3
Intraglomerular hypertension induces fluid shear stress,
hyperfiltration, and proteinuria.4,5 The proteinuria be-
comes part of a vicious cycle by further activating the
local renin-angiotensin system (RAS). Angiotensin II,
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apart from its vasoconstrictory effects, induces local proin-
flammatory signaling molecules such as transforming
growth factor- (TGF-), transforming necrosis factor-
(TNF-), RANTES, or membrane cofactor protein-1
(MCP-1) at the tubulointerstitial level, ultimately leading
to increased matrix deposition, interstitial scarring, and
glomerular sclerosis.1,5
Genetics, RAS, and the
Progression of Chronic
Renal Failure in Children
Since information on candidate genes became available,
several researchers have investigated the role of genetics
and its correlation to BP in chronic renal disease. The
angiotensin converting enzyme (ACE) gene polymor-
phism has received most attention so far, the DD genotype
being associated with increased transcription of the gene,
higher circulating levels of ACE, and more rapid progres-
sion in a variety of renal diseases,6 without clear-cut
correlation to systemic BP levels. In children, the ACE
genotype has been found to be unrelated to the occurrence,
but strongly related to the prognosis, of malformations of
the urinary tract; renoparenchymal scarring in children
with vesicorenal reflux almost exclusively occurred in
children with the DD genotype,7 and this genotype was
also a strong independent risk factor for the progressive
loss of renal function in children with hypoplastic or
dysplastic kidneys.8 In the absence of systemic BP
changes, the local intrarenal activity of the RAS and its
noncirculatory profibrotic effects are supposed to explain
these observations.
Lessons From Nephrology
in Adults: Diabetic and
Nondiabetic Nephropathies
The association of hypertension with rapid progression of
renal damage has been recognized for decades. However,
it was unclear whether hypertension was the cause or
merely a marker of progression—and thereby, whether
lowering of BP would be beneficial.
Diabetic nephropathy has served as an excellent model
to investigate progressive renal disease, as many young
patients with this rather uniform disease have been fol-
lowed by teams of clinicians devoted to clinical research,
initially in Scandinavian countries. Years before the avail-
ability of ACE inhibitors, clinical studies demonstrated
that lowering BP to what was then considered upper
normal range9 or lower10 slowed down the loss of renal
function and yielded a simultaneous decrease in protein-
uria. Larger studies fully confirmed these results.11
Several studies performed in adults with nondiabetic
renal disease have also found a high risk of progression of
chronic renal insufficiency associated with high BP,12 and
a beneficial effect of lowering BP for the preservation of
renal function.13,14
A particular risk of rapid progression seems to be
associated with nocturnal hypertension.15 We do not yet
know whether restoring the nocturnal BP dipping might
optimize the renoprotective effect of antihypertensive
treatment in chronic renal disease.
The ACE inhibitors seemed to offer better preservation
of renal function than other antihypertensive agents,16
most importantly in proteinuric patients.17 In most studies,
BP was slightly better controlled in the group who re-
ceived ACE inhibitors. In the absence of ambulatory blood
FIG. 1. Pathophysiology consequences of hypertension in damaged kidneys. ATR-1 angiotensin-II receptor type 1; ATR-2 angiotensin-II
receptor type II. Note the two loops of vicious cycle, proteinuria and the activation of profibrotic signaling molecules. Note also the protective
action of the ATR-2; this activation by high circulating and local angiotensin II levels may explain the suggested additive benefit of
ATR-1-antagonists; RAS  renin-angiotensin system.
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pressure monitoring recordings, the difference may even
have been underestimated; ACE inhibitors seem to have
particular advantages for nocturnal BP control, which es-
capes observation by casual BP. Additional benefit has
been attributed to the inhibition of “local” actions of
angiotensin II, that is, glomerular hypertension and hyper-
filtration, proteinuria, and trophic proinflammatory ef-
fects.18 Recent studies suggest that angiotensin II receptor
antagonists offer at least similar renoprotection.
Pediatric Renal Disease
Children with chronic renal failure represent a unique
population. In contrast to adults with chronic renal insuf-
ficiency, glomerulopathies (including diabetic nephropa-
thy) are rare disorders in this age group, and the largest
population is children with reduced renal mass. Most of
these patients have normal or only slightly elevated BP,
modest proteinuria, and a natural course of slow progres-
sion. Would BP still be correlated to the progression of
CRF under these circumstances?
In a pediatric prospective multicenter study,19 a casual
systolic BP of more than 120 mm Hg, as well as a
moderate proteinuria (50 mg/kg body weight per day)
proved to be significant risk factors for progression of
renal failure, whereas the protein content of the diet had no
influence (Fig. 2). Thus, the progression of renal failure in
children with reduced renal mass appears to be correlated
to the same risk factors as in adults, and it could be
speculated that the optimal prevention for progression of
CRF in adults—aggressive BP lowering and inhibition of
the RAS—should offer renoprotection in children as well.
The evidence of renoprotection by ACE inhibitors, as
well as their antihypertensive efficacy with little side ef-
fects, have lead to a widespread use of these agents in
pediatric renal patients despite few published pediatric
data. Therefore, a controlled study to evaluate ACE inhib-
itors in children with chronic renal insufficiency actually
seems unacceptable for ethical as well as for practical
reasons.
The benefit of aggressive BP control for the progression
of chronic renal failure in children is addressed by an
ongoing European multicenter study. Patients aged 3 to 18
years with a GFR between 15 and 75 mL/min/1.73 m2 and
a spontaneous BP above the 50th percentile are observed
for 3 years with regular evaluation of ABPM and GFR.
For the ethical reasons described previously, all patients
receive ramipril. They are randomized to a target BP
below the height-related 50th percentile, or between the
50th and the 95th percentile, based on the ABPM 24-h
means. The feasibility and patient tolerance of such inten-
sified BP control in children with CRF seems to be good.
The final results of the study are expected in 2004.
In conclusion, large studies in adults with diabetic or
nondiabetic renal disease have shown the association of
high BP with rapid progression of CRF, the benefit of
decreasing BP, and the specific advantages of ACE inhib-
itors. For children, the correlation of BP to the rate of CRF
progression was shown. Although the efficacy of renopro-
tection by ACE inhibitors has not been (and probably will
never be) demonstrated in controlled pediatric trials, it
appears highly likely based on the results in adults and the
proven renal risk inferred by high BP and proteinuria in
children with chronic renal disease. The optimal target BP
for children with CRF is currently being determined.
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